Capmatinib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 288 publications
Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer.
Journal: Lung cancer management
Published: April 04, 2026
A novel NIR fluorescent probe based on p-mercaptophenylboronic acid-functionalized copper nanoclusters for capmatinib quantification.
Journal: Analytical methods : advancing methods and applications
Published: March 30, 2026
A tri-scale in silico framework integrating pharmacovigilance and mechanistic modeling suggests tepotinib-associated acute kidney injury risk.
Journal: Renal failure
Published: January 25, 2026
Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer by concurrent integrin and MET signaling.
Journal: Science signaling
Published: December 23, 2025
Safety and Synergy of Capmatinib Plus Stereotactic Radiotherapy in MET Exon 14-Mutated Non-Small Cell Lung Cancer: A Case Report.
Journal: Cureus
Published: December 20, 2025
Correction: Capmatinib for the treatment of METex14 skipping non-small cell lung cancer: retrospective analysis of real-world data from patients receiving compassionate use treatment in Italy.
Journal: Clinical and experimental medicine
Published: December 17, 2025
Real-world evidence for 10 oncology drugs approved in the last 5 years: A comprehensive narrative synthesis.
Journal: Critical reviews in oncology/hematology
Published: December 08, 2025
Real-World Evidence for 10 Oncology Drugs Approved in the last 5 years: A Comprehensive Narrative Synthesis.
Journal: Critical reviews in oncology/hematology
Published: December 08, 2025
Targeting Mesenchymal-Epidermal Transition (MET) Aberrations in Non-Small Cell Lung Cancer: Current Challenges and Therapeutic Advances.
Journal: Cancers
Published: November 27, 2025
Clinical Activity of MET-TKIs in METex14 Skipping NSCLC With Poor Performance Status.
Journal: Anticancer research
Published: November 19, 2025
Real-world adoption of off-label combinations for targeted therapy resistance in non-small cell lung cancer.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: October 13, 2025
Comparative Toxicovigilance of Capmatinib and Tepotinib in NSCLC: Respiratory Signal Detection and Adverse Event Profiling via FAERS.
Journal: Journal of biochemical and molecular toxicology
Published: September 11, 2025
Last Updated: 04/28/2026